Weather analytics platform with Houston HQ taps Norwegian biz to optimize tech

weatherproof tech

StormGeo, a Houston-based weather intelligence provider, has partnered with Norwegian company 7Analytics to create technology positioned to revolutionize planning for floods. Photo courtesy of Kinder Institute

There’s no way around it: Houston floods. And with the deluge comes hurdles for businesses. The only real power we have in the face of such adversity is preparation.

StormGeo, a weather intelligence provider with its United States headquarters in Houston, has partnered with Norwegian company 7Analytics to create technology positioned to revolutionize planning for floods.

StormGeo debuted in Norway in 1997. In 2012, it acquired Houston company Impact Weather, says Bob Weinzapfel, a meteorologist and senior project manager of weather insights for StormGeo. Houston is one of 24 offices spread over 15 countries with more than 600 employees, Weinzapfel adds.

The team at 7Analytics, according to Weinzapfel, “Are a bunch of smart flood experts and machine learning experts.” Together, they are introducing a technology that Weinzapfel calls “a game changer” for Houston businesses.

7Analytics uses AI to give users an overview of Houston’s potential flooding based on a 72-hour forecast. “Any business like a grocery store or hospitals or even a refinery—any business with employees or customers, it’s important to know Are the roadways being flooded? Can my employees and customers get in?” says Weinzapfel.

StormGeo has long provided weather insights and guidance to businesses in Houston. Now, detailed maps provide real-time flood forecasting.

The maps forecast the probability of flash flooding in each subbasin, but perhaps more importantly, they can home in on clients’ buildings to show what inundation will look like in parking lots and nearby roads.

"Our product takes a real-time StormGeo weather forecast — for example, the risk of rainfall tomorrow—and translates it into actionable risk info, such as their site is at risk of up to a foot of flooding tomorrow with peak flood occurring at 2 p.m.," explains Jonas Toland, co-founder of 7Analytics.

Armed with such information, businesses can adjust operations ahead. For example, one client is a grocery store chain.

“They have business processes they have to get a jump on. The locations that have customers try to be the last to close and first to open,” Weinzapfel says.

That means that storm tracking can help with letting the store’s team know to purchase more emergency supplies to sell, schedule more employees to help sell them, and know when to close to keep those workers safe.

The Houston version of the solution is the first, but Weinzapfel says that the team is currently working to expand across greater Houston and then into Austin.

“We knew if we could do it here and do a really good job, we could do it anywhere using the same technology,” he adds.

There’s no question that flooding will continue to take place in Houston. But with StormGeo and 7Analytics’ Houston-area flood model, the people that serve us will be prepared.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

Houston biotech startup secures $10M seed round to propel cancer-fighting therapy from bench to bedside

fresh funding

A Houston biotech company based off research out of UTHealth Houston has raised seed funding to continue developing its cancer-fighting therapeutic.

CrossBridge Bio, formed during the TMC Innovation’s Accelerator for Cancer Therapeutics program, closed a $10 million seed round led by TMC Venture Fund and Crescent Enterprises' VC arm, CE-Ventures. The round also included participation from Portal Innovations, Alexandria Venture Investments, Linden Lake Labs, and several pre-seed investors.

“We are thrilled to have the support of such experienced investors who share our vision of bringing transformative cancer therapies to patients in need,” Michael Torres, CEO of CrossBridge Bio, says in a news release. Torres served as an entrepreneur in residence of ACT.

The company is working on the next-generation of antibody-drug conjugates (ADC) therapeutics that process dual payloads as targeted treatments for a set of challenging cancers. The innovative treatment is based on research from UTHealth experts Dr. Kyoji Tsuchikama and Dr. Zhiqiang An.

“Our dual-payload ADC technology is designed to deliver synergistic therapeutic effects using highly stable linkers that ensure payload release only within the targeted cancer cells, thereby maximizing their therapeutic effectiveness while minimizing the liabilities associated with uptake in unintended tissues, as seen with many of today’s cancer treatments," Torres continues.

He explains that the funding will toward advancing CrossBridge's first development candidate, CBB-120, into preclinical non-GLP toxicology studies in addition to derisking the company’s proprietary linker technology with dual-payload applications, per the release.

As a result of the raise, William McKeon, president and CEO of the Texas Medical Center, and Damir Illich, manager of life sciences of CE-Ventures, will join CrossBridge Bio’s board of directors.

“We are proud to back CrossBridge Bio in their mission to develop the next generation of cancer therapies,” McKeon says in the release. “Their dual-payload ADCs are designed to deliver targeted drug release within cancer cells with greater stability, precision, and control. These breakthrough advancements have the potential to change patients’ lives worldwide and we look forward to helping drive their development.”

Houston firm scores 2 grants to support testing treatment for addiction, neurodegenerative diseases

money moves

A Houston organization devoted to developing early-stage therapeutic and medical device technologies announced fresh funding for one of its startups.

Fannin Partners' Goldenrod Therapeutics, received a $320,000 Phase I SBIR grant from the National Institute on Drug Abuse (NIDA) for studies regarding both addiction medicine and neurodegenerative diseases with a single lead candidate, called 11h.

The grant will fund studies in rodent models of methamphetamine addiction and the efficacy of 11h for the tiny patients. This is the next step in charting the established promise of 11h in substance use disorders using animal models. Existing therapies for opioid and alcohol addiction have high relapse rates, and there are currently no FDA-approved medications for Stimulant Use Disorders (StUDs).

Previous preclinical studies demonstrated that 11h was effective in the fight against cocaine addiction. The goal is to note similar results in methamphetamine addiction.

At the same time, Fannin was also granted a $250,000 Early Hypothesis Development Award from the Department of Defense (DoD) to study 11h in neurodegenerative diseases. Specifically, the funds will be used to work on rodent models of multiple sclerosis (MS).

Fannin’s goal is to develop an oral medication that slows or reverses the progression of MS, while also improving the patient’s quality of life by relieving symptoms. Many MS medications come with the threat of liver injury and increased risk of infection, so sidestepping those is also a hope for 11h.

In fact, 11h was developed to minimize the toxicities associated with existing PDE4 inhibitors. Early evidence shows that the drug is not only effective, but also safe and easily tolerable.

“NIDA’s continued support of our SUD program highlights the potential of 11h to significantly improve the standard of care for patients suffering from these conditions, some of which lack any approved pharmaceutical options," says Dr. Atul Varadhachary, managing partner at Fannin, in a news release. “The additional DoD funding will allow us to explore 11h’s impact on neurodegenerative disease, as well. We are grateful for the support from both organizations as we advance 11h towards clinical development.”

Previous steps in 11h’s development were funded by a $350,000 Phase I SBIR grant from NIDA. 11h is part of NIDA’s Addiction Treatment Discovery Program. Next year, Fannin will likely scale up Good Manufacturing Practices (GMP) production and complete toxicology studies. This will lead to clinical trials for 11h for cocaine use disorder and other StUDs. But don’t expect Fannin to be quiet for long. Its next big discovery is always on the horizon.

Autonomous truck company taps breaks on Houston-Dallas route

re-routing

Autonomous truck company Aurora Innovation says it won't start hauling freight without humans on board until April of next year, a delay from previous statements that commercial service would begin by the end of 2024.

The Pittsburgh company on Wednesday said the April launch of driverless semis traveling from Dallas to Houston — originally announced last year — will be “modestly later” than the company had intended. The company also previously announced a partnership with Uber.

The company told investors on its third-quarter earnings conference call that it has made progress toward ensuring its trucks will operate safely.

Remaining obstacles are “primarily in the areas of some elements of surface street driving and some elements of construction that we see on the freeway,” CEO Chris Urmson said. “We want to have extremely high confidence in the system as we as we go forward.”

The company will start with about 10 autonomous tractor-trailers and move to “tens” of trucks by the end of next year, Urmson said.

“This shift to our timeline will have a negligible financial impact and does not affect our scaling efforts on our path to self-funding," Urmson said.

Aurora also intends to haul freight without human drivers from Fort Worth, Texas, to Phoenix later in 2025, Urmson said.

Aurora in August added nearly $500 million to its balance sheet with a capital raise in August, which the company expects to fund the initial phases of its strategy to scale up driverless trucking.

View All Listings